Physician profile
Steven C Behrendsen
NPI 1306812656
$2,324.67
in general payments reported to CMS, 2019-2025
25 companies · $68.18 in 2025
The $68.18 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $28.80 · 2020: $44.93 · 2021: $28.54 · 2022: $684 · 2023: $1,034 · 2024: $437 · 2025: $68.18.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,380 · Education: $159.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,379.74 |
| Education | $158.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $473.92 | 2021-2024 | Rinvoq, Skyrizi |
| Janssen Biotech, INC. | $344.99 | 2022-2024 | Tremfya, Stelara, Remicade |
| Amgen INC. | $283.73 | 2020-2024 | Enbrel, Otezla, Tavneos |
| Ucb, INC. | $217.27 | 2022-2024 | Cimzia |
| Novartis Pharmaceuticals Corporation | $152.75 | 2022-2025 | |
| Pfizer INC. | $109.86 | 2019-2024 | |
| Astrazeneca Pharmaceuticals LP | $68.74 | 2022-2024 | |
| Mallinckrodt Hospital Products INC. | $66.95 | 2022-2023 | Acthar |
| Corcept Therapeutics | $60.97 | 2023 | Korlym |
| Alexion Pharmaceuticals, INC. | $60.60 | 2022 | |
| Aurinia Pharma U.S., INC. | $59.59 | 2022 | |
| Lilly USA, LLC | $57.76 | 2022-2023 | Taltz |
| E.R. Squibb & Sons, L.L.C. | $54.87 | 2020-2023 | Orencia |
| Novo Nordisk INC | $46.23 | 2022-2023 | Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $37.34 | 2023-2024 | Cyltezo, Ofev |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ibsa Pharma INC. | $35.65 | 2023-2024 | Tirosint, Licart, Licart |
| Pharming Healthcare, INC. | $30.18 | 2024 | Ruconest |
| Actelion Pharmaceuticals US, INC. | $28.05 | 2023 | Uptravi, Opsumit |
| Sobi, INC | $24.77 | 2023 | |
| Merck Sharp & Dohme LLC | $24.56 | 2025 | Verquvo, Capvaxive |
| Daiichi Sankyo INC. | $19.57 | 2023 | Injectafer |
| Vifor Pharma, INC. | $17.70 | 2023 | Veltassa, Korsuva |
| Glaxosmithkline, LLC. | $16.60 | 2023 | Benlysta |
| Procept Biorobotics Corporation | $16.44 | 2025 | |
| Nestle Healthcare Nutrition INC. | $15.58 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Behrendsen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.